Intradermal vaccination for infants and children

Saitoh, Akihiko; Aizawa, Yuta

doi:10.1080/21645515.2016.1176652

Cited by 14 publications

(8 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Second, improved or alternative methods of administering vaccines should be considered. Recent studies have shown that a potent immune response can be induced by intradermal vaccination, and that dose-sparing can be achieved [118]. To date, no Hib vaccine has been evaluated for intradermal administration, although the advantages and potential downsides of this delivery method have been discussed [119].…”

Section: Expert Opinionmentioning

confidence: 99%

Haemophilus influenzae type b disease in the era of conjugate vaccines: critical factors for successful eradication

Slack

Esposito

Haas

et al. 2020

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Prior to implementation of Haemophilus influenzae type b (Hib)-conjugate vaccination programs in the 1990s, Hib was the commonest cause of bacterial meningitis in children aged <5 years. While the burden of all Hib disease has significantly decreased in the post-vaccination era, Hib still accounted for >29,000 deaths worldwide in children aged <5 years in 2015. Areas covered: We reviewed literature data on the most widely used Hib vaccines and vaccination strategies which led to the global prevention and control of Hib disease and aim to highlight important factors for continued disease control and elimination in the future. Expert commentary: More than 90% of countries worldwide have implemented Hib-conjugate vaccination in their national immunization programs. Vaccines containing Hib polyribosylribitol phosphate (PRP) conjugated with tetanus toxoid (Hib-TT) are the most commonly used. Neisseria meningitidis outer membrane protein complex of PRP (Hib-OMP) is also used. Although the kinetics of the immune response varies with Hib vaccine and schedule used, high control of Hib disease was observed in all settings/scenarios. Further improving global Hib vaccination coverage may result in disease elimination.

show abstract

Section: Expert Opinionmentioning

confidence: 99%

Haemophilus influenzae type b disease in the era of conjugate vaccines: critical factors for successful eradication

Slack

Esposito

Haas

et al. 2020

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…Les premières reposent sur des systèmes sans aiguille [37]. Cette voie d'administration permet par ailleurs de limiter la quantité d'antigène nécessaire pour obtenir une réponse immunitaire similaire à la voie IM, ce qui a pu être constaté dans de nombreuses études menées notamment chez l'enfant [38]. Certains dispositifs sont utilisables avec les formats de vaccin existants (flacons ou ampoules), d'autres font partie intégrante du vaccin lui-même (vaccins à délivrance muqueuse).…”

Section: Les Nouvelles Méthodes De Délivrance Des Vaccinsunclassified

Les vaccins de demain

Lelièvre

2019

Revue Francophone des Laboratoires

View full text Add to dashboard Cite

La vaccination représente une des avancées majeures dans le domaine de la santé. Les premiers vaccins ont été produits sur un concept assez empirique reposant sur la stratégie des « 3 i » : isolement, inactivation, injection. Plus récemment sont apparus les vaccins protéiques. Cependant l'émergence de nouveaux pathogènes, l'inefficacité des stratégies vaccinales actuelles pour protéger contre certaines infections, la nécessité de pouvoir développer rapidement et à bas coût de revient des vaccins ont conduit à développer de nouveaux types de vaccins. C'est dans ce contexte que se sont développés des vaccins basés sur l'utilisation des séquences codantes d'acides nucléiques des antigènes d'intérêt (vecteurs viraux, vaccins ADN, vaccins ARN) visant à améliorer l'efficacité des vaccins actuellement disponibles et à proposer des plateformes génériques potentiellement utilisables contre un grand nombre de pathogènes différents. Outre l'utilisation de ces nouveaux vaccins, les recherches vaccinales en cours bénéficient d'évolutions technologiques visant à délivrer de manière optimale les vaccins, en ciblant par exemple les cellules dendritiques, et de mieux caractériser les antigènes d'intérêt via notamment l'utilisation de la vaccinologie inverse. ABSTRACT Vaccine of the futureVaccination represents one of the major advances in the field of health. The first vaccines were produced on a rather empirical concept based on the so-called 3I strategy: isolation, inactivation, injection. More recently, protein vaccines have emerged. However, the emergence of new pathogens, the inefficiency of these vaccine strategies to protect against several infections, the need to be able to develop new vaccines quickly and at low cost have led to the development of new types of vaccines. In this context vaccines based on the use of the nucleic acid coding sequences of the antigens of interest (viral vectors, DNA vaccines, RNA vaccines) have been developed in order to improve the efficiency of the currently available vaccines and to propose generic platforms potentially usable against a large number of different pathogens. In addition to the use of these new vaccines, ongoing vaccine research is benefiting from technological developments aimed at optimally delivering vaccines, targeting, for example, dendritic cells, and better characterizing the antigens of interest through the use of vaccines of reverse vaccinology. MOTS CLÉS◗ pathogènes émergents ◗ vaccin ADN ◗ vaccin ARN ◗ vaccinologie inverse ◗ vecteurs viraux KEY WORDS ◗ DNA vaccine ◗ emerging infectious diseases ◗ reverse vaccinology ◗ RNA vaccine ◗ viral vectors

show abstract

“…These DCs efficiently take up and present antigens, thereby eliciting innate and adaptive immune responses . In addition, ID vaccination requires less vaccine to induce strong prophylactic responses compared to SC and IM routes, suggesting significant dose‐sparing and cost‐saving benefits …”

Section: Introductionmentioning

confidence: 99%

“…[10][11][12] In addition, ID vaccination requires less vaccine to induce strong prophylactic responses compared to SC and IM routes, suggesting significant dose-sparing and cost-saving benefits. [13][14][15][16] Despite the immunological and economic advantages, ID administration using conventional needles and syringes shows technical difficulties. To overcome such drawbacks, easy-to-use delivery devices have been introduced, including an adapter for existing needles and syringes, a microneedle and a needle-free jet injector.…”

mentioning

confidence: 99%